XML 37 R26.htm IDEA: XBRL DOCUMENT v3.25.3
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2025
Collaborative Arrangements [Abstract]  
Schedule of Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Alliance revenue - Lynparza$379 $337 $1,061 $947 
Alliance revenue - Koselugo (1)
214 39 301 114 
Total alliance revenue$593 $376 $1,362 $1,061 
Cost of sales (2)
84 82 253 245 
Selling, general and administrative31 39 103 121 
Research and development3 19 31 57 
($ in millions)September 30, 2025December 31, 2024
Receivables from AstraZeneca included in Other current assets (3)
$436 $424 
Payables to AstraZeneca included in Accrued and other current liabilities (4)
4 713 
(1)    Amounts in 2025 include the $150 million upfront payment and $50 million regulatory milestone triggered in the third quarter as a result of the amendment to the collaboration agreement noted above.
(2)    Represents amortization of capitalized milestone payments.
(3)    Balance at September 30, 2025 includes a milestone receivable.
(4)    Balance at December 31, 2024 includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Alliance revenue - Lenvima$258 $251 $781 $755 
Cost of sales (1)
60 60 181 181 
Selling, general and administrative33 40 99 120 
Research and development2 4 10 18 
($ in millions)September 30, 2025December 31, 2024
Receivables from Eisai included in Other current assets
$258 $257 
(1)    Represents amortization of capitalized milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Alliance revenue - Adempas/Verquvo$112 $102 $340 $306 
Net sales of Adempas recorded by Merck82 72 229 214 
Net sales of Verquvo recorded by Merck12 11 33 25 
Total sales$206 $185 $602 $545 
Cost of sales (1)
71 59 190 182 
Selling, general and administrative22 29 80 88 
Research and development11 27 55 82 
($ in millions)September 30, 2025December 31, 2024
Receivables from Bayer included in Other current assets
$168 $160 
Payables to Bayer included in Accrued and other current liabilities
93 82 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Net sales of Lagevrio recorded by Merck
$138 $383 $323 $843 
Cost of sales (1)
81 204 178 491 
Selling, general and administrative
11 11 39 43 
Research and development
11 5 25 7 
($ in millions)September 30, 2025December 31, 2024
Payables to Ridgeback included in Accrued and other current liabilities (2)
$49 $68 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
(2)    Includes accrued royalties.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Cost of sales (1)
$67 $— $67 $— 
Selling, general and administrative 8 5 21 21 
Research and development
110 94 379 227 
($ in millions)September 30, 2025December 31, 2024
Receivables from Daiichi Sankyo included in Other current assets
$17 $8 
Payables to Daiichi Sankyo included in Accrued and other current liabilities (2)
869 817 
(1)    Represents Merck’s share of certain inventory-related costs.
(2)    Includes accrued continuation payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2025202420252024
Selling, general and administrative $7 $5 $19 $11 
Research and development (1)
96 93 272 255 
($ in millions)September 30, 2025December 31, 2024
Payables to Moderna included in Accrued and other current liabilities
$13 $57 
(1)    Includes amortization of shared facility costs.